Dr Devam J Patel

MD (HOMEOPATH)
गुजरात प्रांत प्रमुख जिज्ञासा आयाम
@ABVPGujarat #RSS

[Dr Devam J Patel @DevamJPatel]

આજ રોજ રાષ્ટ્રિય યુવા દિવસ તથા ભારતના આધ્યાત્મિક ગુરુ, ભારતીય વિચારના પ્રખર પ્રવક્તા, યુવાનોના પ્રેરણાસ્ત્રોત સ્વામી વિવેકાનંદજીની નિમિત્તે અખિલ ભારતીય વિદ્યાર્થી પરિષદ આણંદ (@abvp_anand) દ્વારા હરિ ૐ નગર સેવાવસ્તીમા ફ્રી હોમીઓપેથી મેડિકલ કેમ્પનું આયોજન કરવામાં આવ્યું.

[ABVP Gujarat @ABVPGujarat]

#ABVPGujarat દ્વારા 10+2 મહત્તમ સદસ્યતા દિવસ નિમિત્તે 63,000 સદસ્યતા કરવા બદલ સર્વે કાર્યકર્તા તેમજ વિદ્યાર્થીઓને અભિનંદન....

#JoinABVP

[Internal Medicine @pgMedicine]

Cavitary lung lesions are not diagnosed by one CT sign.
Think pattern first: single vs multiple, upper vs dependent, wall thickness, air-fluid level, immune status, and TB risk.

#CavitaryLungLesions #Pulmonology #InternalMedicine #Radiology #DrAkifJehangir

[Erman Akkus @Erman_Akkus]

🫀Cardiac disease in cancer patients
ESMO guideline summary

#cancer #oncology #MedX #cardiac

[Luis Moreno Sánchez @radioncoluis]

Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore—A Review of Recent Therapeutic Advances.

https://t.co/aSWFoomDiI

[🦠 Dr. Ahmed Alanazi @o_o_dr]

Not all dialysis is the same 🩺🩸

📌 Hemodialysis (HD)
📌 Peritoneal Dialysis (PD)
📌 Continuous Renal Replacement Therapy (CRRT)

Knowing when to choose each modality is just as important as knowing when dialysis is needed.

💉 Hemodialysis → Most common, rapid solute removal
🏠 Peritoneal Dialysis → Home-based, gentler fluid shifts
🏥 CRRT → Preferred in hemodynamically unstable ICU patients

Remember the classic indications for urgent dialysis:

⚡ Hyperkalemia
🩸 Severe Acidosis
☠️ Intoxications
💧 Fluid Overload
🧠 Uremia

A practical review of dialysis modalities, indications, advantages, complications, and high-yield nephrology pearls 📚

https://t.co/1dSdJ0pv1C

[Dr Amol Akhade @SuyogCancer]

What's new data at ESMO Gynae 2026 ?
This is my list 🙂👇.
I Will share the data as it is presented. Starting from today . @myESMO #esmogynae26

[MV Chandrakanth @ChandrakanthMv]

Not all patients receiving moderately emetogenic chemotherapy (MEC) carry the same risk of chemotherapy-induced nausea and vomiting (CINV).

The MyRisk trial tested a simple but important concept: combine patient-specific risk factors with chemotherapy risk to guide antiemetic prophylaxis.

Among high-risk MEC patients, risk-adapted escalation with NEPA + dexamethasone improved:

• Complete response: 81.0% vs 71.8%
• No emesis: 95.4% vs 86.7%
• Complete protection: 71.8% vs 62.4%

Perhaps the most important message:

Treat the patient's emetic risk, not just the chemotherapy's emetic risk.

#Oncology #MedicalOncology #SupportiveCare #CINV #Antiemetics #MASCC #ESMO #ASCO #MVOnco

[Erman Akkus @Erman_Akkus]

🟧Localized Rectal Cancer- ESMO 2025 guideline summary

#cancer #oncology #MedX #rectal @OncoAlert

[Dr. Foxpaws Fauxpas @foxpaws_onco]

Grades of #chemotherapy response across tumors

Higher is better in - Osteosarcoma Huvos, Ovarian CRS, Miller Payne Breast, Dvorak Rectum

Lower is better in - Ryan CAP/Mandard/Becker GI malignancies, #RCB in breast
#onctwitter #oncology #cancer #medtwitter #pathology

[Dr Rishabh Jain @DrRishabhOnco]

HER2-low TNBC may be entering the ADC + IO era.

BEGONIA arm 6 tested 1L durvalumab + T-DXd in HR-negative, HER2-low metastatic breast cancer.

👩‍⚕️ n=58
🧬 Mostly PD-L1 negative
🎯 ORR: 62.1%
⏳ mPFS: 12.6 months
🧭 mOS: 30.3 months

But the signal comes with a warning:

ILD/pneumonitis: 20.7%
Grade 5 ILD: 1.7%

My take:
Promising efficacy, especially in a difficult biology, but this is still phase 1b/2, single-arm, small n, and missed its protocol-defined ORR target.

ADC + IO is exciting.

But toxicity monitoring will decide how far this strategy can go.

🔖 Save this for breast oncology updates.

📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #BreastCancer #TNBC @OncoAlert @myesmo @esmo_open

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

🧬 Can you predict the cytogenetics before the FISH returns?

After seeing thousands of myeloma patients, certain morphology and clinical phenotypes start to become familiar.

Myeloma often whispers its biology before the genomic report arrives.

More to see in the figure 👇

#myeloma #hemetwitter

[MV Chandrakanth @ChandrakanthMv]

Practice-Changing ASCO 2026 Updates 🇮🇳

Several ASCO 2026 studies reinforced a common message: improve outcomes by treating earlier, personalizing therapy, and avoiding unnecessary treatment.

🔹 PROTEUS showed that perioperative apalutamide improved pathologic response and reduced future metastatic events in high-risk localized prostate cancer.

🔹 ARACOG highlighted that treatment choices can affect cognition, with darolutamide associated with less cognitive decline than enzalutamide.

🔹 EMERALD-3 moved immunotherapy-based combinations earlier into the management of embolization-eligible HCC.

🔹 ASTRUM-006 demonstrated that biomarker-selected perioperative immunotherapy can improve outcomes in resectable gastric cancer.

🔹 CHRONO reminded us that more treatment is not always better—additional chemotherapy improved surgical outcomes but did not improve DFS.

The key takeaway:
✅ Intensify earlier when it matters
✅ Preserve quality of life
✅ Move immunotherapy earlier
✅ Personalize treatment intensity
✅ Avoid overtreatment

#ASCO2026 #Oncology #CancerResearch #GUOnc #GIOnc #GynOnc #MedTwitter #MVOnco

[Erman Akkus @Erman_Akkus]

📙Renal and hepatic dose adjustment for oncologists

#cancer #oncology #MedX #drug #treatment #therapy #renal #kidney #hepatic #liver @OncoAlert

[Dr Rupam Manna MD @DrRupamOncology]

🧑‍⚕️ Two patients. Two different stories. One important question:

Which ADC should we choose next in metastatic breast cancer —
Sacituzumab Govitecan or Datopotamab Deruxtecan?

This infographic compares both ADCs using real clinical scenarios (HR+/HER2-negative vs TNBC) based on latest trial data.

Save this for your next case discussion 👇

[MV Chandrakanth @ChandrakanthMv]

TRIPLE-NEGATIVE BREAST CANCER #ASCO2026

A clear theme emerged this year:

From immunotherapy-driven gains in early disease to ADC-driven advances in metastatic TNBC.

Key takeaways:

🔹 KEYNOTE-522: Durable 7-year survival benefit

🔹 ASCENT-04: ADC + IO moves into 1L PD-L1+ mTNBC

🔹 ASCENT-03: SG benefit observed across biomarker groups

🔹 TROPION-Breast02: Dato-DXd validates the TROP2 ADC class

🔹 PANKU-BREAST02: Bispecific ADCs represent the next wave of innovation

ASCO 2026 reinforced the transition from conventional chemotherapy toward ADC-based precision therapy in TNBC.

#TNBC #BreastCancer #ASCO #Oncology #ADC #SacituzumabGovitecan #DatoDXd #MVOnco

[Dr Rupam Manna MD @DrRupamOncology]

Diagnosis of Chronic Lymphocytic Leukemia (CLL) – High-Yield Summary

CLL diagnosis is based on the iwCLL criteria:

• Absolute clonal B-cell count ≥ 5 × 10⁹/L in peripheral blood
• Present for at least 3 months
• Characteristic immunophenotype on flow cytometry (CD5⁺ CD19⁺ CD23⁺ with dim CD20 and weak surface Ig)

Flow cytometry is the most important diagnostic test. The hallmark is co-expression of CD5 and CD23.

This infographic also covers:
• Typical peripheral smear findings (including smudge cells)
• Matutes/CLL scoring system
• When bone marrow biopsy is indicated
• Essential molecular testing (especially TP53/del17p before treatment)
• CLL vs Monoclonal B-cell Lymphocytosis (MBL)

Save this for exam preparation.

#CLL #ChronicLymphocyticLeukemia #MedicalOncology #Hematology #ExamPrep

[MV Chandrakanth @ChandrakanthMv]

HER2-positive breast cancer at #ASCO2026 was about more than efficacy.

This year taught us:

🎯 Better HER2 targeting (KN026)

📉 Smarter de-escalation (IRIS-A, HELEN)

💥 T-DXd continues to redefine HER2+ disease (DESTINY-Breast09)

⚠️ Toxicity monitoring matters (HER2CLIMB-05, DESTINY-Breast05)

The biggest lessons were not just which therapies work—but how to use them more intelligently.

#BreastCancer #HER2 #ASCO2026 #Oncology #MVOnco

[Dr Rupam Manna MD @DrRupamOncology]

Endocrine Resistance in HR+ Breast Cancer: PI3K–AKT–mTOR Pathway & Targeted Therapies (2025–2026)

Understanding the mechanisms of endocrine resistance is critical for optimizing treatment in HR+ metastatic breast cancer.

This infographic covers:

• Key mechanisms driving resistance (PIK3CA, AKT1, PTEN alterations, ESR1 mutations)
• Current targeted therapy options: Capivasertib, Inavolisib, Alpelisib & Everolimus
• Biomarker-driven treatment selection
• Updated preferred sequencing in 2025–2026
• High-yield clinical pearls for exam and practice

A practical, evidence-based resource for medical oncologists, fellows, and residents.

Save this for your next HR+ breast cancer case.

#BreastCancer #EndocrineResistance #PI3K #AKT #mTOR #MedicalOncology #DrRupamManna

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Highlights of the Year in Breast Cancer #ASCO26
✨Optimal Management With Antibody Drug Conjugates Across Breast Cancer Stages and Subtypes
@DrWGradishar 🎙️✨
@OncoAlert #OncoAlertAF #BreastCancer